Myocardial Infarction News and Research

RSS

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

5 Sep 2011

Stent for Life Initiative aims to support implementation of primary PCI in the ESC countries

Primary PCI is the best reperfusion therapy for patients presenting with acute ST-elevation myocardial infarction. CJ Terkelsen and co-workers used the Western Denmark Heart Registry to describe the implementation of primary PCI in Denmark.

30 Aug 2011

CMR predicts increased risk of sudden cardiac death in patients with myocardial infarction

Universitätsmedizin Berlin and Universität Leiden developed a method to identify a subgroup of patients with myocardial infarction that is at increased risk for sudden cardiac death.

30 Aug 2011

Balloon pump use prior to PCI does not reduce infarct size in STEMI patients without shock

Intra-aortic balloon pump counterpulsation prior to PCI in patients with ST segment elevation MI does not reduce infarct size as measured by MRI, according to results from the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction (CRISP AMI) trial.

30 Aug 2011

Xience V stent performs well in patients with primary PCI for ST elevation myocardial infarction

The second generation drug-eluting stent Xience V performs well in patients having primary PCI for ST elevation myocardial infarction, and has a better safety profile than that of bare metal stents, according to results of the EXAMINATION trial.

30 Aug 2011

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.

30 Aug 2011

Intra-aortic balloon counterpulsation prior to PCI does not reduce infarct size in AMI patients

Inserting intra-aortic balloon pumps prior to angioplasty in patients with acute myocardial infarction (AMI) does not reduce the scope of heart muscle damage, a condition referred to as infarct size, according to a new study conducted by Duke University Medical Center researchers.

30 Aug 2011

Everolimus-eluting stent reduces incidence of stent thrombosis

Results of the independently-funded Bern-Rotterdam cohort study provide robust evidence of an "important" reduction in overall and very late stent thrombosis.

30 Aug 2011

Post myocardial infarction snus quitters have 44% lower risk of mortality

In this prospective cohort study, presented today at the ESC Congress 2011, discontinuation of smokeless tobacco after a myocardial infarction (MI) is associated with a lower risk of subsequent mortality. Investigators found that post MI snus quitters had a 44 % lower risk of total mortality.

29 Aug 2011

PCI linked with higher risk of adverse events in patients with triple vessel disease than CABG

Results from CREDO-Kyoto PCI/CABG Registry Cohort-2 show that percutaneous coronary intervention (PCI) was associated with significantly higher risk for serious adverse events in patients with triple vessel disease than coronary artery bypass grafting.

29 Aug 2011

Post MI snus quitters have lower risk of mortality

29 Aug 2011

Physio-Control announces commercial availability of ReadyLink 12-Lead ECG device

Physio-Control, Inc., a global leader in emergency medical solutions and wholly‐owned subsidiary of Medtronic, Inc.,, today announced commercial availability of the ReadyLink™ 12-Lead ECG device, a new, U.S. Food and Drug Administration (FDA) 510(k)-cleared solution designed to improve care for heart attack patients and expand regional STEMI systems.

From Medtronic 24 Aug 2011

Trophos awarded US patent covering use of novel cardioprotective compound

Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).

23 Aug 2011

Almost all heart attack patients receive angioplasty within 90 minutes of being admitted

Almost all heart attack patients who need the emergency artery-opening procedure known as angioplasty are receiving it within 90 minutes of being admitted to the hospital, a marked improvement from five years ago when most patients waited longer for the life-saving procedure, according to a report by Yale School of Medicine researchers and their colleagues.

23 Aug 2011

AstraZeneca announces availability of BRILINTA tablets in the U.S. pharmacies

AstraZeneca today announced that BRILINTA tablets, a new oral antiplatelet therapy, is now available in pharmacies in the United States.

23 Aug 2011

Calcium scores and heart disease risk, experts debate

...

22 Aug 2011

OrbusNeich's Genous Stent safe, effective for patients at high risk of restenosis

OrbusNeich today announced that the that the company's Genous Stent showed no significant difference in the rate of target vessel failure (TVF) at two years compared to the Taxus Liberte™ paclitaxel-eluting stent in patients with de novo coronary artery lesions carrying a high risk for restenosis.

17 Aug 2011

Researchers demonstrate contribution of Immunoglobulin E to atherogenesis

There is an observed correlation between Immunoglobulin E (IgE) levels atherosclerosis, with twice amount of IgE present in patients with acute myocardial infarction as in patients with stable angina or without coronary heart disease (CHD). Guo-Ping Shi, DSc, Jing Wang, MD, PhD, and colleagues in the Department of Medicine at Brigham and Women's Hospital (BWH), have demonstrated the direct participation of IgE in atherogenesis in a mouse model.

10 Aug 2011

One third of patients do not receive follow-up care for depression across Ontario

Twenty-five percent of people who were hospitalized for depression were readmitted or visited an emergency room again for depression within 30 days of discharge, according to a new study by the Centre for Addiction and Mental Health.

4 Aug 2011

New research highlights urgent need to develop specific guidelines for HIV-infected children

Children with HIV have persistently high levels of cholesterol and other lipids during treatment with antiretroviral medications, according to a pair of studies in JAIDS: Journal of Acquired Immune Deficiency Syndromes.

4 Aug 2011

Myocardial Infarction News and Research

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Stent for Life Initiative aims to support implementation of primary PCI in the ESC countries

CMR predicts increased risk of sudden cardiac death in patients with myocardial infarction

Balloon pump use prior to PCI does not reduce infarct size in STEMI patients without shock

Xience V stent performs well in patients with primary PCI for ST elevation myocardial infarction

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

Intra-aortic balloon counterpulsation prior to PCI does not reduce infarct size in AMI patients

Everolimus-eluting stent reduces incidence of stent thrombosis

Post myocardial infarction snus quitters have 44% lower risk of mortality

PCI linked with higher risk of adverse events in patients with triple vessel disease than CABG

Post MI snus quitters have lower risk of mortality

Physio-Control announces commercial availability of ReadyLink 12-Lead ECG device

Trophos awarded US patent covering use of novel cardioprotective compound

Almost all heart attack patients receive angioplasty within 90 minutes of being admitted

AstraZeneca announces availability of BRILINTA tablets in the U.S. pharmacies

Calcium scores and heart disease risk, experts debate

OrbusNeich's Genous Stent safe, effective for patients at high risk of restenosis

Researchers demonstrate contribution of Immunoglobulin E to atherogenesis

One third of patients do not receive follow-up care for depression across Ontario

New research highlights urgent need to develop specific guidelines for HIV-infected children

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News